Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and tdap vaccines

Pediatrics

Volumn 136, Issue 3, 2015, Pages e563-572

  Schilling, Andrea ^a   Parra, Mercedes Macias ^b   Gutierrez, Maricruz ^c   Restrepo, Jaime ^d   Ucros, Santiago ^e   Herrera, Teobaldo ^f   Engel, Eli ^g   Huicho, Luis ^h   Shew, Marcia ⁱ   Maansson, Roger ^j   Caldwell, Nicole ^j   Luxembourg, Alain ^j   Meulen, Ajoke Sobanjo Ter ^j  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c Hospital para el Nino Poblano   (Mexico)

^d Fundación Centro de Investigación Clínica   (Colombia)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^f INSTITUTO DE INVESTIGACIÓN NUTRICIONAL   (Peru)

^g Bayview Research Group   (United States)

^h INSTITUTO NACIONAL DE SALUD DEL NIÑO   (Peru)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; TETANUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TETANUS; TETANUS PROPHYLAXIS; VACCINATION; WART VIRUS; CLINICAL TRIAL; IMMUNIZATION; PROCEDURES; UNITED STATES;

ADOLESCENT; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION SCHEDULE; MALE; MENINGOCOCCAL VACCINES; UNITED STATES; VACCINATION;

EID: 84940859502     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-4199     Document Type: Article

References (24)

1. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38
2. de Sanjosé S, Alemany L, Ordi J, et al; HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450-3461
3. Alemany L, Saunier M, Alvarado-Cabrero I, et al; HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1): 98-107
4. Alemany L, Saunier M, Tinoco L, et al; HPV VVAP study group. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014;50(16):2846-2854
5. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(suppl 3): S3-, 35-41
6. Joura EA, Giuliano AR, Iversen O-E, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723
7. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136(1): e28-e39
8. Prescribing Information. GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant). Revised: February 2015. Available at: http://www.merck.com/product/usa/pi-circulars/g/gardasil-9/gardasil-9-pi.pdf. Accessed April 28, 2015
9. Petrosky E, Bocchini JA Jr, Hariri S, et al; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-304
10. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218-226
11. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet. 2006; 368(9548):1706-1728
12. Broder KR, Cortese MM, Iskander JK, et al; Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1-34
13. European Centre for Disease Prevention and Control (ECDC) Guidance-Scientific panel on childhood immunization schedule: diphtheria-tetanus-pertussis (DTP) vaccination. 2009. Available at http://www.ecdc.europa.eu/en/publications/Publications/0911-GUI- Scientific-Panel-on-Childhood- Immunisation-DTP.pdf. Accessed October 17, 2014
14. Cohn AC, MacNeil JR, Clark TA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1-28
15. Prescribing Information. Menactra meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine). Revised: August 2014. Available at: http://www.sanofipasteur. us/vaccines. Accessed October 17, 2014
16. Prescribing Information. Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed). Revised: March 2014. Available at: http://www.sanofipasteur.us/vaccines. Accessed October 17, 2014
17. Roberts C, Green T, Hess E, et al. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother. 2014;10(8):2174-103 doi:10.4161/hv.29205
18. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985; 4(2):213-226
19. Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J. 2015; 34(6):627-634 doi:10.1097/INF.0000000000000694
20. Reisinger KS, Block SL, Collins-Ogle M, et al; Protocol 025 Investigators. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics. 2010; 125(6):1142-1151
21. Vaccine Working Party (VWP) Conclusions from the Workshop on Coadministration of Vaccines held on 31 Jan-1 Feb 2006. January 16, 2007. Doc. Ref: EMEA/CHMP/VWP/14684/2007. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Other/2009/11/WC500015459.pdf. Accessed June 18, 2015
22. Schuchat A. HPV "coverage." N Engl J Med. 2015;372(8):775-776
23. Centers for Disease Control and Prevention. Immunization schedules: birth-18 years and catch-up immunization schedules. Available at: http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html. Accessed March 22, 2015
24. Noronha AS, Markowitz LE, Dunne EF. Systematic review of human papillomavirus vaccine coadministration. Vaccine. 2014;32(23):2670-2674